3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Phase NA
2
Phase 1/2
1
Phase 1
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
2
Dermatologic
2
Breast
2
Sarcoma
1
Head & Neck
1
CNS
1
Conditions
Sarcoma
160
Glioblastoma
86
Gliosarcoma
79
Brain Neoplasms
52
Central Nervous System Neoplasms
47
Osteosarcoma
43
Astrocytoma
40
Sarcoma, Ewing
39
Neoplasm Metastasis
37
Melanoma
35
Rhabdomyosarcoma
34
Neoplasms
34
Ovarian Neoplasms
33
Glioma
32
Neuroblastoma
30
Breast Neoplasms
30
Oligodendroglioma
29
Lymphoma
28
Recurrence
27
Colorectal Neoplasms
26
Carcinoma, Non-Small-Cell Lung
25
Dendritic Cell Sarcoma, Interdigitating
22
Stomach Neoplasms
21
Lymphoma, Non-Hodgkin
21
Gastrointestinal Stromal Tumors
20
Carcinoma, Renal Cell
19
Sarcoma, Synovial
18
Pancreatic Neoplasms
18
Lymphoma, Follicular
18
Neurofibrosarcoma
17
Interventions
selinexor
1
Pharmaceutical Preparations
1
Imatinib Mesylate
1
Drug Combinations
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Drug-Related Side Effects and Adverse Reactions
×
Sarcoma
×
Clear all
NCT04138381
2023-03-27
SeliGIST
Grupo Espanol de Investigacion en Sarcomas
Phase 1/2
Unknown
30 enrolled